About ADMA Biologics
ADMA Biologics (NASDAQ:ADMA) is a biopharmaceutical company deeply engaged in the development, manufacturing, and marketing of plasma-derived products for the treatment and prevention of infectious diseases. Their operations focus primarily on immune globulins, a class of medicines vital for people with weakened immune systems. A key aspect of their mission is to improve patient outcomes in immune-compromised and other patient populations across the globe. Through dedicated research and strategic collaborations, ADMA Biologics aims to expand its product portfolio, ensuring access to life-saving therapies for individuals in need. Their objectives center around advancing the quality and safety of plasma-derived therapies, increasing their market presence, and playing a pivotal role in the fight against infectious diseases by bringing innovative solutions to the healthcare sector.
Snapshot
Operations
Products and/or services of ADMA Biologics
- BIVIGAM, an IVIG product for treating patients with primary humoral immunodeficiency.
- ASCENIV, an IVIG immune globulin for immune compromised patients.
- Nabi-HB, a hepatitis B immune globulin for acute exposure to hepatitis B.
- Plasma collection centers, operational facilities for collecting and processing plasma.
- Respiratory syncytial virus (RSV) immune globulin, a specialized treatment for RSV.
- Contract manufacturing services, offering plasma fractionation and purification.
ADMA Biologics executive team
- Mr. Adam S. GrossmanCo-Founder, President, CEO & Director
- Dr. Jerrold B. Grossman D.P.S., Ph.D.Co-Founder & Vice Chairman of the Board
- Mr. Brad TadeCFO & Treasurer
- Ms. Kaitlin KestenbergCOO & Senior VP of Compliance
- Mr. Michael GoldsteinGeneral Counsel
- Mr. John HaflExecutive Director of Sales
- Mr. Skyler BloomSenior Director of Business Development & Corporate Strategy